Orbifloxacin API Manufacturers & Suppliers

Orbifloxacin is a fluoroquinolone antibiotic primarily indicated for use in veterinary medicine, specifically approved for treatment of bacterial infections in dogs. It belongs to the quinoline carboxylic acid chemical class, characterized by a quinoline ring substituted with a carboxyl group. Orbifloxacin exhibits broad-spectrum antibacterial activity typical of fluoroquinolones, targeting a range of Gram-negative and Gram-positive pathogens associated with canine infections.

The mechanism of action of orbifloxacin involves inhibition of bacterial DNA gyrase and topoisomerase IV enzymes, essential for DNA replication, transcription, and repair. This inhibition leads to disruption of bacterial DNA processes, resulting in bactericidal effects. Orbifloxacin may also interact with human cytochrome P450 enzymes, notably acting as an inhibitor of CYP1A2, which has implications for potential drug-drug interactions.

Pharmacokinetic data highlight that orbifloxacin has favorable absorption following administration, with distribution properties suitable for targeting relevant tissues in veterinary patients. The drug undergoes metabolism with partial involvement of the cytochrome P450 system and is eliminated primarily via renal excretion. Specific parameters such as bioavailability, half-life, and volume of distribution are documented in veterinary pharmacology references but vary based on formulation and species.

Safety and toxicity considerations include a potential for adverse effects common to fluoroquinolones, such as cartilage toxicity in growing animals and risks associated with QTc interval prolongation, underlying the need for cautious use in animals with predisposing conditions. Orbifloxacin's classification as a potential QTc-prolonging agent warrants attention in clinical contexts. Resistance development is a known concern for fluoroquinolone antibiotics.

Orbifloxacin is marketed under veterinary pharmaceutical formulations by Schering-Plough Animal Health. In procurement and quality assurance of orbifloxacin active pharmaceutical ingredient (API), attention should be given to its chemical purity, polymorphic form, residual solvents, and compliance with relevant pharmacopoeial standards. Reliable sourcing from manufacturers with validated quality control processes is critical to ensure consistent performance and safety in veterinary applications.